Adalimumab

Although major adverse cardiac events, malignancy and venous thromboembolism are more frequent in at-risk patients with rheumatoid arthritis, rates are similar between those receiving upadacitinib vs. adalimumab, according to data.

The hotly debated topic of interchangeability between biologics and biosimilars has officially leapt from the hypothetical realm to clinical practice, ushering in a new era of therapy switching in rheumatology.

Comorbidities, health care utilization and costs are increasing for patients with hidradenitis suppurativa, prompting a need for better disease management, according to a study.

Secukinumab and adalimumab demonstrate similar efficacy regarding the resolution of enthesitis over 52 weeks in patients with psoriatic arthritis, according to data published in Rheumatology.

Cyltezo, the first interchangeable Humira biosimilar, officially entered the U.S. market on July 1, opening a floodgate that will see the release this month of half a dozen biosimilars for what has been the top selling drug in the country.

Patients with psoriatic arthritis and axial involvement experienced greater improvement when treated with upadacitinib 15 mg compared with placebo and adalimumab, according to data published in Arthritis Research & Therapy.

Amjevita, Cigna’s adalimumab biosimilar that made its U.S. marketplace debut in January, has so far failed to make an impact among patients compared with the reference drug, according to a physician survey.

Increased adalimumab dosage may improve disease severity in patients with overweight or obesity with moderate to severe hidradenitis suppurativa, according to a study.

Coherus BioSciences’ adalimumab biosimilar, Yusimry, will make its debut in the U.S. marketplace this summer at an 85% discount compared with the originator Humira, according to the manufacturer.

The hidradenitis suppurativa-IGA score strongly correlated with other measures of the condition’s activity and may be more useful for clinicians, according to a study.